Long term outcome of patients treated on clinical trials of immunomodulatory agents for the treatment of Immunoglobulin light chain (AL) amyloidosis: A pooled analysis

Am J Hematol. 2019 Jul;94(7):E194-E196. doi: 10.1002/ajh.25497. Epub 2019 May 3.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bortezomib / administration & dosage*
  • Disease-Free Survival
  • Female
  • Humans
  • Immunoglobulin Light-chain Amyloidosis* / blood
  • Immunoglobulin Light-chain Amyloidosis* / drug therapy
  • Immunoglobulin Light-chain Amyloidosis* / mortality
  • Immunologic Factors / administration & dosage*
  • Male
  • Middle Aged
  • Survival Rate

Substances

  • Immunologic Factors
  • Bortezomib

Grants and funding